State of Global Rectal Microbicide Research

42
State of Global Rectal Microbicide Research Ian McGowan MD PhD FRCP Magee-Womens Research Institute University of Pittsburgh

description

State of Global Rectal Microbicide Research. Ian McGowan MD PhD FRCP Magee-Womens Research Institute University of Pittsburgh. - PowerPoint PPT Presentation

Transcript of State of Global Rectal Microbicide Research

Page 1: State of Global Rectal Microbicide Research

State of Global Rectal Microbicide Research

Ian McGowan MD PhD FRCP

Magee-Womens Research Institute

University of Pittsburgh

Page 2: State of Global Rectal Microbicide Research

Microbicides are products that can be applied to the vaginal or rectal mucosa with the intent of

preventing or significantly reducing the risk of acquiring

STIs including HIV

Page 3: State of Global Rectal Microbicide Research

McGowan I, Biologicals, 2006

Microbicide Mechanism of Action

Page 4: State of Global Rectal Microbicide Research

Rationale for Rectal Microbicides

Unprotected receptive anal intercourse (RAI) is the highest risk sexual activity for HIV transmission

Men and women in the developed and developing world practice RAI

Murine and non human primate studies have shown proof of concept that rectal application of ARV microbicides can prevent SIV/HIV infection

Page 5: State of Global Rectal Microbicide Research

Lubricants As a Drug Delivery System

Page 6: State of Global Rectal Microbicide Research

MSM

DevelopedWorld

Women

0

10

20

30

40

50

Seattle St. Louis New Orleans

Per

cen

tag

e (%

)

DevelopingWorld

Page 7: State of Global Rectal Microbicide Research

Clinical Development of Rectal Microbicides

Page 9: State of Global Rectal Microbicide Research

Early Nonoxynol-9 Studies

Low-dose N-9 gel was not associated with macroscopic rectal and penile epithelial disruption or inflammation, but histologic abnormalities were commonly observed during N-9 gel as well as during placebo gel use. Tabet S et al. Sex Trans Dis 1999

2% N-9 showed rapid exfoliation of the rectal epithelium. Phillips D et al. Contraception 2004

Page 10: State of Global Rectal Microbicide Research

HPTN 056 Study Design

Screening

Week - 2 0 + 2 + 4

Baseline Week 2 Week 4

ConsentPhysicalAnoscopyRectal GC/CHHIV AbCD4 / Viral load

SigmoidoscopyIntestinal biopsy at 10cm and 30cmCell isolation and flow cytometryTissue cytokinesRectal immunoglobulinsTissue / rectal secretion viral load

McGowan et al. JAIDS 2007

Page 11: State of Global Rectal Microbicide Research

UC781 Trial Design

Screening Enrollment Randomization

0.1%

0.25%

Placebo

Baseline Endoscopy

Single dose2nd

Endoscopy7 singleDoses

3rd

Endoscopy

Anton P et al. PLoS ONE 2011

Page 12: State of Global Rectal Microbicide Research

Explant Data (TCID50 102)

0

1000

2000

3000

4000

5000

6000

7000

V2 V3

Visit

Cu

mu

lati

ve P

-24

at D

ay 1

4 (p

g/m

l)

0

1000

2000

3000

4000

5000

6000

7000

V2 V3Visit

Cu

mu

lati

ve P

-24

at D

ay 1

4 (p

g/m

l)

(ID=41 0)

0

1000

2000

3000

4000

5000

6000

7000

V2 V3Visit

Cu

mu

lati

ve P

-24

at D

ay 1

4 (p

g/m

l)

0

1000

2000

3000

4000

5000

6000

7000

V2 V3Visit

Cu

mu

lati

ve P

-24

at D

ay 1

4 (p

g/m

l)

0

1000

2000

3000

4000

5000

6000

7000

V2 V3Visit

Cu

mu

lati

ve P

-24

at D

ay 1

4 (p

g/m

l)

0

1000

2000

3000

4000

5000

6000

7000

V2 V3Visit

Cum

ulat

ive

P-24

at D

ay

14 (p

g/m

l)

HEC Placebo UC781 0.10% UC781 0.25%

10cm

30cm

V2: Baseline; V3: 30 minutes post single dose

Page 13: State of Global Rectal Microbicide Research

Oral or Topical ARV PrEP?

Oral

Topical

Concentration of ARV

Blood Mucosa

Page 14: State of Global Rectal Microbicide Research

RMP-02/MTN-006

BaselineEvaluation

Open labelOral tenofovir

(N = 18)

Single rectal

tenofovir(N = 18)

2:1

7 DayRectal

tenofovir(N = 18)

2:1

Safety, PK / PD, acceptability

Anton et al. CROI 2011

Page 15: State of Global Rectal Microbicide Research

Rectal Acceptability of Vaginal Tenofovir

0

20

40

60

80

PlaceboTenofovir

Like Discomfort Likelihood ofUse

% o

f p

arti

cip

ants

Page 16: State of Global Rectal Microbicide Research

Pharmacokinetics in TissueC

on

cen

tra

tion

of T

VF

-DP

(fm

ol/m

g)

Route Oral Rectal (S) Rectal (7D)

N Detectable 7/18 10/12 12/12

Page 17: State of Global Rectal Microbicide Research

PK/PD Relationship

0 1 2 3 40

5000

10000

15000

r2 = 0.33P = 0.0011

Oral Dose Single Rectal Dose Multiple Rectal Dose

Log10[Tissue TFV-DP ]fmol/mg

Cum

ulati

ve p

24 (p

g/m

L)

Page 18: State of Global Rectal Microbicide Research

Mucosal Safety in RM Trials Epithelial sloughing Histopathology Mucosal mononuclear cell

phenotype Mucosal cytokine mRNA Luminex Microarray gene

expression Fecal calprotectin Rectal microflora

N-9

PRÉ

Page 19: State of Global Rectal Microbicide Research

MTN-007

N=60

HEC(N=15)

1% Tenofovir

(N=15)

2% N-9(N=15)

Single dose

7 day daily doses

7-14 dayinterval

EndoscopySafety/behavioral

assessment

ScreeningNo

Treatment(N=15)

BaselineEvaluation

7-14 dayinterval

Page 20: State of Global Rectal Microbicide Research

DAIDS Integrated Preclinical Clinical Program for HIV Topical

Microbicides

Page 21: State of Global Rectal Microbicide Research

Microbicide Development Program

First IPCP focusing on rectal microbicide development

Provided proof of concept in the SIV NHP model and development of explant platform

Phase 1 clinical trials of the vaginal formulation of tenofovir gel UC781 (RMP-01) Tenofovir (RMP-02/MTN-006)

Behavioral correlates of RAI

Anton: IPCP U19 AI060614 / August 2004

Page 22: State of Global Rectal Microbicide Research

CHARM Program Combination HIV Antiretroviral Rectal

Microbicide Program NIAID/DAIDS Integrated Preclinical Clinical

Program Consortium

University of Pittsburgh UCLA Johns Hopkins UNC CONRAD / Gilead

McGowan: IPCP U19 AI082637 / September 2009

Page 23: State of Global Rectal Microbicide Research

CHARM Program Overview Development of rectal specific ARV

microbicides PK/PD evaluation in humanized mouse

model Phase 1 studies

Tenofovir Maraviroc Tenofovir & Maraviroc

Page 24: State of Global Rectal Microbicide Research

CHARM-01 Pre-Phase 1 single dose comparison of

current formulations of tenofovir 1% gel: Vaginal formulation Reduced glycerin formulation Rectal specific formulation

Endpoints General and mucosal safety PK/PD

Current status Version 1.0

Page 25: State of Global Rectal Microbicide Research

CHARM-02

Pre-Phase 1 single dose comparison of current formulations of tenofovir 1% gel with and without simulated RAI

Endpoints Pharmacokinetics Drug distribution using SPECT/CT imaging

Current status Version 1.0

Page 26: State of Global Rectal Microbicide Research

Project Gel

McGowan & Carballo-Dieguez: NICHD R01 / September 2009

Page 27: State of Global Rectal Microbicide Research

Microbicide Safety and Acceptability in Young Men

NICHD R01 Pittsburgh, Boston, Puerto Rico

Phase 1 safety and acceptability of tenofovir 1% gel Ethnically diverse MSM (18-30) Consensual RAI in last month Unprotected RAI in last year

Page 28: State of Global Rectal Microbicide Research

Microbicide Safety and Acceptability in Young Men

Stage 1A

Screening

240 MSM

Consensual RAI in last month

URAI in last year

Stage 1B

3 month Acceptability & Adherence study with

placebo gel

120 MSM

RAI in last 3 months

STI negative

Stage 2

Phase 1 Tenofovirrectal

safety study

42 MSM

80% adherence in Stage 1B

Page 30: State of Global Rectal Microbicide Research

MTN-017

Phase 2 rectal safety study of tenofovir gel

N = 210 International sites

United States (3) Thailand (2) South Africa (1) Peru (1)

Endpoints Safety Adherence

Self report Objective

measures Acceptability PK/PD

Page 31: State of Global Rectal Microbicide Research

MTN-01712 weeks 12 weeks 12 weeks

BLTNF Gel

Daily

TNF Gel

ID

Oral

Truvada

BLTNF Gel

ID

TNF Gel

Daily

Oral

Truvada

BLOral

Truvada

TNF Gel

ID

TNF Gel

Daily

Mucosal PK/PD subset

Page 33: State of Global Rectal Microbicide Research

Combination Prevention

SC ± Oral ± Rectal ± Vaginal

Conventional HIV Prevention Package + PrEP

± HIV Vaccine

Page 34: State of Global Rectal Microbicide Research

iPrEx Study 2,499 MSM and male-

to-female transgendered women randomized to Truvada or placebo

44% reduction in HIV acquisition

Higher drug concentrations associated with increased protection

Grant R et al. NEJM 2010

Page 35: State of Global Rectal Microbicide Research

TMC-278 LA Rilpivirine NNRTI IM Nanosuspension Potential for 1-3 month

delivery Phase 1 PK/PD studies

ongoing Colorectal explants Cervicovaginal explants

MWRI-01* University of Pittsburgh Liverpool University

*Funded by the Bill and Melinda Gates Foundation

Page 36: State of Global Rectal Microbicide Research

Arm 1

Arm 2

Arm 3

Arm 4

1200mg

1200mg

600mg 600mg600mg

600mg

900mg 900mg

1200mg + 900mg/ 3 monthlyPossible Arm 5

Possible Arm 5/6 300mg/ 1 monthly600mg/2 monthly

Initial Enrollment Secondary Enrollment

Screen Baseline +1 +2 +3 +4 +5

MWRI-01

Page 37: State of Global Rectal Microbicide Research

Effectiveness Study Designs

Option 1: Tenofovir gel versus placebo + standard prevention package

Option 2: Tenofovir gel versus placebo + standard prevention package + permission to use PrEP (HVTN 505)

Option 3: Tenofovir gel versus placebo + standard prevention package + Truvada

Option 4: Tenofovir gel versus Truvada versus TMC 278 LA + standard prevention package

Page 38: State of Global Rectal Microbicide Research

Sample Size Parameters

Assumptions Incidence rate ~ 5% Effect size 60% Lower bound 25% Minimum FU 12

months Enrollment

300/month PrEP effect 46% Endpoints: 120

Option1 N = 2,400; FU 24

months Option 2

N = 2,400; FU 30 months

Option 3 N = 2,400; FU 37

months

Page 39: State of Global Rectal Microbicide Research

The VOICE Trial

Both oral and topical tenofovir arms stopped for futility

Reasons for failure not yet known Non adherence Compartmental PK Biology

Implications for rectal microbicide development?

Page 40: State of Global Rectal Microbicide Research

Rectal Microbicide Timeline*

2010 2011 2012 2013 2014 2015 2016 2017 2018

Phase 1

Phase 2

Phase 2B

Review

Available

Vaginal microbicides

*An approximation based on tenofovir 1% gel

Page 41: State of Global Rectal Microbicide Research

Summary Rectal microbicides are needed for men and

women in the developed and developing world who are at risk of HIV associated with unprotected RAI

RM development has moved from Phase 1 to Phase 2

PK/PD models should increase likelihood of success in Phase 2B/3

Planning for an RM effectiveness study needs to start now.